[1]张 璇,杨 静.多发性骨髓瘤患者血清miR-424，miR-363-3p水平表达与病情进展及预后相关性研究[J].现代检验医学杂志,2025,40(01):43-47.[doi:10.3969/j.issn.1671-7414.2025.01.008]
　ZHANG Xuan,YANG Jing.Study on the Correlation between Serum miR-424, miR-363-3p Levels and Disease Progression and Prognosis in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2025,40(01):43-47.[doi:10.3969/j.issn.1671-7414.2025.01.008]
点击复制

多发性骨髓瘤患者血清miR-424，miR-363-3p水平表达与病情进展及预后相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第40卷
期数:
2025年01期
页码:
43-47
栏目:
论著
出版日期:
2025-01-15

文章信息/Info

Title:
Study on the Correlation between Serum miR-424, miR-363-3p Levels and Disease Progression and Prognosis in Patients with Multiple Myeloma
文章编号:
1671-7414（2025）01-043-05
作者:
张 璇; 杨 静
（西安市人民医院/ 西安市第四医院，西安710000）
Author(s):
ZHANG Xuan; YANG Jing
（Xi’an People’s Hospital/Xi’an Fourth Hospital，Xi’an 710000，China）
关键词:
多发性骨髓瘤;  微小RNA-424; 微小RNA-363-3p
分类号:
R551.3；R392.11
DOI:
10.3969/j.issn.1671-7414.2025.01.008
文献标志码:
A
摘要:
目的 分析多发性骨髓瘤（MM）患者血清miR-424，miR-363-3p 水平与病情进展的关系及联合预测预后的价值。方法 研究纳入2022 年1 月～ 2023 年9 月西安市人民医院收治的MM 76 例为研究组，国际分期系统Ⅰ期（n=19）、Ⅱ期（n=27）和Ⅲ期（n=30）；免疫分型明确IgA 型（n=16）、IgG 型（n=43）、轻链型（n=11）和非分泌型（n=6）；纳入同期体检健康志愿者75 例为健康对照组。检测各组血清miR-424，miR-363-3p 水平；行Logistic 因素分析及绘制受试者工作特征（ROC）曲线探究miR-424，miR-363-3p 在MM 病情进展及预后中的关系。结果 研究组miR-424 水平（2.77±0.61）高于健康对照组（0.83±0.26），miR-363-3p 水平（0.49±0.09）低于健康对照组（1.20±0.21），差异具有统计学意义（t=25.362，27.064，均P ＜ 0.05）；Ⅲ期MM 患者miR-424 水平显著高于I 期、Ⅱ期患者（t=11.988，10.366），miR-363-3p 低于I 期、Ⅱ期患者（t=8.077，5.543），差异具有统计学意义（均P ＜ 0.05）；IgG 型MM 患者miR-424 水平显著高于IgA 型、轻链型、非分泌型（t=5.967，5.358，3.960），miR-363-3p 水平显著低于IgA 型、轻链型、非分泌型（t=11.594，8.013，6.994），差异具有统计学意义（均P ＜ 0.05）；预后不良MM 患者Cys-C，miR-424 水平显著高于预后良好组，miR-363-3p 水平低于预后良好组，差异具有统计学意义（t=3.067，6.137，4.011，均P＜ 0.05）。miR-424，miR-363-3p 诊断MM的最佳截断值分别为1.73，0.40，联合诊断ROC曲线AUC（95%CI）：0.911（0.801 ～ 0.973）高于miR-424［0.792（0.685 ～ 0.822）］与miR-363-3p［0.761（0.669 ～ 0.798）］，差异具有统计学意义（Z=6.026，7.769，均P<0.05）。结论 血清miR-424 高水平表达，miR-363-3p 低水平表达提示MM 病情进展与不良预后，联合检测血清miR-424，miR-363-3p 可用于预测MM 病情进展及预后。
Abstract:
Objective To analyze the relationship between serum levels of miR-424 and miR-363-3p and disease progression in patients with multiple myeloma (MM), and the value of combined prediction of prognosis. Methods A total of 76 patients with MM admitted to Xi’an People’s Hospital from January 2022 to September 2023 were included in the study group. There were 19 patients in the International Staging System Phase I, 27 patients in Phase I, and 30 patients in Phase III. Immunological classification confirmed 16 cases of IgA type, 43 cases of IgG type, 11 cases of light chain type, and 6 instances of nonsecretory type. 75 healthy volunteers who underwent physical examinations during the same period were included as the healthy control group. Detected the serum levels of miR-424 and miR-363-3p between groups, perform Logistic factor analysis, and draw receiver operating characteristic (ROC) curves to explore the relationship between miR-424 and miR-363-3p in the progression and prognosis of MM. Results The miR-424 (2.77 ± 0.61) level in the study group was higher than that in the healthy control group (0.83 ± 0.26), and the miR-363-3p level (0.49 ± 0.09) was lower than that in the healthy control group (1.20 ± 0.21), with statistically significant differences (t=25.362，27.064，all P<0.05)．The miR-424 level in stage III MM patients was significantly higher than that in stage I, stage II patients (t=11.988，10.366), and miR-363-3p was lower than that in stage I, stage II MM patients (t=8.077, 5.543), with statistically significant differences (all P<0.05)．The miR-424 levels in IgG type MM patients were significantly higher than those in IgA type, light chain type, and non secretory type (t=5.967，5.358，3.960)，and the miR-363-3p levels were significantly lower than those in IgA type，light chain type, and non secretory type (t=11.594，8.013， 6.994) , with statistically significant differences (all P<0.05)．The levels of Cys-C and miR-424 in MM patients with poor prognosis were significantly higher than those in the good prognosis group, while the levels of miR-363-3p were lower than those in the good prognosis group, with statistically significant differences (t=3.067，6.137，4.011，all P<0.05) ．The optimal cut-off values for miR-424 and miR-363-3p in diagnosing MM were 1.73 and 0.40, respectively. The AUC（95%CI） of the combined diagnosis ROC curve[0.911(0.801~0.973)]was higher than that of miR-424[0.792(0.685~0.822) ] and miR-363- 3p[0.761(0.669~0.798)], and the differences were statistically significant (t=6.026, 7.769，all P<0.05). Conclusion High levels of serum miR-424 expression and low levels of miR-363-3p expression suggested MM progression and poor prognosis. The combination of serum miR-424 and miR-363-3p has a high value in predicting the progression and prognosis of MM.

参考文献/References:

[1] MOHTY M, CAVO M, FINK L, et al. Understanding mortality in multiple myeloma: findings of a European retrospective chart review [J]. European Journal of Haematology, 2019, 103(2): 107-115.
[2] HAN S, WOO S, KIM Y I, et al. Prognostic value of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in newly diagnosed multiple myeloma: a systematic review and meta-analysis[J]. European Radiology, 2021, 31(1): 152-162.
[3] YANG Yongming, WU Zhifeng, WANG Ming. MicroRNA-429 regulates invasion and migration of multiple myeloma cells via Bmi1/AKT pathway[J]. Journal of Biomaterials and Tissue Engineering, 2022，12(12): 2419-2426.
[4] POURHANIFEH M H, MAHJOUBIN-TEHRAN M, SHAFIEE A, et al. MicmRNAs and exosomes： small molecules with big actions in multipie myeloma pathogenesis[J]. IUBMB Life, 2020, 72(3): 314-333.
[5] 肖仕珊， 朱红倩．miR-424 靶向PTEN 基因调控IL-6/STAT3 信号通路影响骨髓瘤细胞增殖和凋亡的机制[J]. 中国老年学杂志, 2023,43(24):6113-6118. XIAO Shishan, ZHU Hongqian. Mechanism of miR-424 targeting PTEN gene to regulate IL-6/STAT3 signaling pathway and affect proliferation and apoptosis of myeloma cells [J]. Chinese Journal of Gerontology, 2023, 43(24): 6113-6118.
[6] 刘会永，李彦，黄燕．溃疡性结肠炎患者血浆miR-106a 和miR-363-3p 表达水平的变化及意义[J]．国际消化病杂志，2019，39（5）：341-346． LIU Huiyong, LI Yan, HUANG Yan. Changes and significance of plasma miR-106a and miR-363-3p expression in patients with ulcerative colitis [J]. International Journal of Digestive Diseases, 2019, 39(5): 341-346.
[7] SHAIKH S P, IRFAN S M, SHEIKH S S . Disease staging according to international scoring system in newly diagnosed patients with multiple myeloma [J]. Pakistan Journal of Medical Sciences，2019，35(1)：90-94.
[8] 中国医师协会血液科医师分会，中华医学会血液学分会．中国多发性骨髓瘤诊治指南（2022 年修订）[J]．中华内科杂志，2022，61（5）：480-487． Chinese Hematology Association，Chinese Society of Hematology，Chinese Medical Association. Guidelines for the diagnosis and management of multiple myeloma in China (2022 revision) [J]. Chinese Journal of Internal Medicine, 2022, 61(5): 480-487.
[9] 原瑞凤, 董玉君, 李春蕊, 等. 初治多发性骨髓瘤患者细胞遗传学异常流行病学的多中心回顾性研究[J]. 中华血液学杂志, 2020, 41(1):10-15． YUAN Ruifeng, DONG Yujun, LI Chunrui, et al. Epidemiological analysis of cytogenetic abnormalities in patients with newly-diagnosed multiple myeloma:a multi-center retrospective study [J]. Chinese Journal of Hematology, 2020, 41(1): 10-15.
[10] 况小红，童浩，代明辉，等．全球多发性骨髓瘤发病和死亡现状及其与人类发展指数的关系[J]. 现代肿瘤医学，2021,29(2):302-306． KUANG Xiaohong, TONG Hao, DAI Minghui, et al. The incidence and mortality of multiple myeloma in the world and its relationship with national levels of human development index [J]. Journal of Modern Oncology, 2021, 29(2): 302-306.
[11] MOREAU P, SAN MIGUEL J, SONNEVELD P, et al. Multiple myeloma: ESMO Clinical practice guidelines for diagnosis, treatment and follow-up[J]. Annals of Oncology, 2017, 28(suppl_4): iv52-iv61.
[12] GALLI M, CHATTERJEE M, GRASSO M, et al. Phase I study of the heparanase inhibitor roneparstat: an innovative approach for ultiple myeloma therapy[J]. Haematologica, 2018, 103(10): e469-e472.
[13] BABION I, SNOEK B C, NOVIANTI P W, et al. Triage of high-risk HPV-positive women in populationbased screening by miRNA expression analysis in cervical scrapes; a feasibility study [J]. Clinical Epigenetics, 2018, 10: 76.
[14] 周瑜辉，张伟，孙静岚，等．miR-455-5p 在乳腺癌组织中表达及对乳腺癌MCF-7 细胞增殖和侵袭的影响[J]. 中华实用诊断与治疗杂志,2021,35(4):340-344. ZHOU Yuhui, ZHANG Wei, SUN Jinglan, et al. Expression of miR-455-5p in breast cancer and its influence on the proliferation and invasion of MCF-7 cells [J]. Journal of Chinese Practical Diagnosis and Therapy, 2021, 35(4): 340-344.
[15] HANDA H, MURAKAMI Y, ISHIHARA R, et al. The role and function of microRNA in the pathogenesis of multiple myeloma[J]. Cancers (Basel), 2019, 11(11): 1738.
[16] 黄娟娟, 卓芬, 蔡月红, 等. 血清miR-424 及miR-765 在多发性骨髓瘤中的表达及其临床意义[J]. 中国实验血液学杂志,2022,30(2):461-465. HUANG Juanjuan, ZHUO Fen, CAI Yuehong, et al. Expression and clinical significance of serum miR-424 and miR-765 in multiple myeloma [J]. Journal of Experimental Hematology, 2022, 30(2): 461-465.
[17] 杜娟英，薛海鲸．多发性骨髓瘤患者血清微小RNA-424, 可溶性晚期糖基化终末产物受体、c-kit受体蛋白检测及临床意义[J]. 陕西医学杂志，2022,51(12):1585-1588, 1592. DU Juanying, XUE Haijing. Detection and clinical significance of serum miR-424, sRAGE and CD117 in patients with multiple myeloma [J]. Shaanxi Medical Journal, 2022, 51(12): 1585-1588, 1592.
[18] 苑军伟，吴静，林静，等．LncRNA NORAD 靶向抑制miR-363-3p 对多发性骨髓瘤细胞生物学行为的影响及机制[J]. 临床与病理杂志,2020,40(7):1650-1657. YUAN Junwei, WU Jing, LIN Jing, et al. Effects of LncRNA NORAD targeted inhibition of miR-363-3p on biological behavior of multiple myeloma cells and its mechanisms [J]. Journal of Clinical and Pathological Research, 2020, 40(7): 1650-1657.
[19] 王玉，李超，满其航．miR-363-3p 在多发性骨髓瘤中的表达意义及其与预后的关系[J]. 临床血液学杂志,2021,34(10):702-705. WANG Yu, LI Chao, MAN Qihang. Significance of plasma miR-363-3p expression in multiple myeloma and its relationship with prognosis [J]. Journal of Clinical Hematology, 2021, 34(10): 702-705.
[20] 黄娟娟, 卓芬, 肖华, 等. 血清miR-424 及miR-520在多发性骨髓瘤中的表达及其临床意义[J]. 现代肿瘤医学,2022,30(7):1268-1272． HUANG Juanjuan, ZHUO Fen, XIAO Hua, et al. Expression and clinical significance of serum miR-424 and miR-520 in multiple myeloma[J]. Journal of Modern Oncology, 2022, 30(7): 1268-1272.
[21] GOROSHINSKAYA I A, FRANZINTZ E M, ZUDERMAN N E, et al. Indicators of kidney damage in patients with multiple myeloma in the process of chemotherapeutic treatment [J]. Klinicheskaia Laboratornaia Diagnostika, 2018, 63(12): 741-749.
[22] 杨敏. 多发性骨髓瘤患者血清Cys-C,Urea,Ser 及β2-MG 水平检测及其临床意义[J]．标记免疫分析与临床，2019, 26(3):506-510. YANG Min. Detection of levels of serum Cys-C，Urea， Scr and β2-MG in patients with multiple myeloma and their clinical significance [J]. Labeled Immunoassays and Clinical Medicine, 2019, 26(3): 506-510.

相似文献/References:

[1]韩秀蕊,杨娣娣,李艳春,等.多发性骨髓瘤患者骨髓涂片与骨髓活检同步检查的比较分析[J].现代检验医学杂志,2015,30(03):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
　HAN Xiu-rui,YANG Di-di,LI Yan-chun,et al.Comparative Analysis of Bone Marrow Smears and Biopsies Synchronous Check for Myeloma Patients[J].Journal of Modern Laboratory Medicine,2015,30(01):129.[doi:10.3969/j.issn.1671-7414.2015.03.039]
[2]邱 爽,孟瑞芳,蒋筱漪,等.血清免疫固定电泳、蛋白电泳、免疫球蛋白及轻链定量在诊断多发性骨髓瘤中的临床应用[J].现代检验医学杂志,2015,30(02):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
　QIU Shuang,MENG Rui-fang,JIANG Xiao-yi,et al.Clinical Application of Immunofixtion Electrophoresis, Serum Protein Electrophoresis and Immunoglobulins and Light Chain Quantitative Analysis in the Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2015,30(01):61.[doi:10.3969/j.issn.1671-7414.2015.02.019]
[3]李 瑛,李 军.多发性骨髓瘤患者血清中IL-6与IL-27水平监测的临床应用[J].现代检验医学杂志,2016,31(04):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
　LI Ying,LI Jun.Clinical Application of Monitoring IL-6 and IL-27 Levels in Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2016,31(01):87.[doi:10.3969/j.issn.16717-414.2016.04.023]
[4]郭进京,胡林辉,陶千山,等.红细胞分布宽度在多发性骨髓瘤患者预后分期中的价值[J].现代检验医学杂志,2017,32(03):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
　GUO Jin-jing,HU Lin-hui,TAO Qian-shan,et al.Value of Red Cell Distribution Width in the Prognosis of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(01):34.[doi:10.3969/j.issn.1671-7414.2017.03.009]
[5]谭 奎,沈婵娟,张 玲,等.多发性骨髓瘤患者骨髓CD269和CD317基因的差异性表达研究[J].现代检验医学杂志,2017,32(06):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
　TAN Kui,SHEN Chan-juan,ZHANG Ling,et al.Differential Expression of CD269 and CD317 Genes in Bone Marrow of Patients with Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2017,32(01):64.[doi:10.3969/j.issn.1671-7414.2017.06.001]
[6]盘国雄,谭才燕,何嘉颖,等.多发性骨髓瘤患者血清中lncRNA PCAT-1的表达水平与临床预后研究[J].现代检验医学杂志,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
　PAN Guo-xiong,TAN Cai-yan,HE Jia-ying,et al.Serum LncRNA PCAT-1 Expression Level of Patients with Multiple Myeloma and Clinical Value[J].Journal of Modern Laboratory Medicine,2018,33(01):72.[doi:10.3969/j.issn.1671-7414.2018.01.001]
[7]刘玉霞,胡国瑜,袁朝晖,等.CD269和CD317在多发性骨髓瘤中的表达及临床意义[J].现代检验医学杂志,2018,33(02):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
　LIU Yu-xia,HU Guo-yu,YUAN Chao-hui,et al.Expression of CD269 and CD317 in Multiple Myeloma and Its Clinical Significance[J].Journal of Modern Laboratory Medicine,2018,33(01):58.[doi:10.3969/j.issn.1671-7414.2018.02.001]
[8]张 蓉,李国辉,刘小五,等.初诊多发性骨髓瘤患者外周血淋巴细胞绝对值/ 单核细胞绝对值比值在预测临床预后的价值研究[J].现代检验医学杂志,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
　ZHANG Rong,LI Guo-hui,LIU Xiao-wu,et al.Value of Peripheral Blood Lymphocyte Absolute Value/Monocyte Absolute Value Ratio in Predicting Clinical Prognosis of Newly Diagnosed MultipleMyeloma Patients[J].Journal of Modern Laboratory Medicine,2020,35(01):101.[doi:10.3969/j.issn.1671-7414.2020.01.027]
[9]霍 豆,秦 爽,吴永昌,等.血清总轻链与游离轻链定量检测在多发性骨髓瘤诊断中的临床价值探讨[J].现代检验医学杂志,2020,35(04):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
　HUO Dou,QIN Shuang,WU Yong-chang,et al.Clinical Value of Quantitative Detection of sTLC and sFLC in Diagnosis of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2020,35(01):87.[doi:10.3969/j.issn.1671-7414.2020.04.021]
[10]何　进,张　艳,申娴娟,等.多发性骨髓瘤患者血清可溶性PD-L1水平在辅助诊断及临床分型的价值研究[J].现代检验医学杂志,2021,36(02):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]
　HE Jin,ZHANG Yan,SHEN Xian-juan,et al.Value of Blood Soluble PD-L1 in the Auxiliary Diagnosis and Clinical Subtype of Multiple Myeloma[J].Journal of Modern Laboratory Medicine,2021,36(01):15.[doi:doi:10.3969/j.issn.1671-7414.2021.02.004]

备注/Memo

备注/Memo:
基金项目：陕西省重点研发计划项目2022SY-193。
作者简介：张璇（1986-），女，硕士，主治医师，研究方向：血液系统疾病，E-mail：hoo39565@163.com。
更新日期/Last Update: 2025-01-15